Qualcomm Ventures led a $70M round in smart-ring maker Ultrahuman at a ~$365M valuation, a year after a US import ban nearly wiped it out.
An AI benchmark leapt from 2.5% to 16% of real freelance jobs in eight months. In Nairobi, that abstract number already erased 40,000 essay-writing livelihoods.
The former Apple and PrimeSense engineers behind Face ID and the Kinect raised a $165M Series C at a $1.6B valuation to fix robots' biggest blind spot: perception.
Nvidia is paying $12.93 billion for Hugging Face, the home of open-source AI and 18 million developers. It's the chipmaker's largest acquisition ever, and it just bought the town square where every AI builder meets.
VAST, the company behind text-to-3D platform Tripo, raised ~$446M across Series B and B+ — pushing AI 3D generation into foundation-model territory.
An AI benchmark leapt from 2.5% to 16% of real freelance jobs in eight months. In Nairobi, that abstract number already erased 40,000 essay-writing livelihoods.
🔥 Gigabyte Just Dropped a $400 WOLED Gaming Monitor and It Changes Everything...
The AI chip company Cerebras Systems — the most prominent challenger to Nvidia's GPU empire — hit the Nasdaq on Thursday under the ticker CBRS and...
> In 2025, startups discovered AI. In 2026, the winners figured out which tools to use and when. Here's the stack the smartest founders are runni...
Bending Spoons is buying Airtable for $1.285 billion in all cash — about 89% below the productivity startup's $11.7B pandemic-era peak, and its first deal since going public.
Eli Lilly is paying up to $2.88 billion for Merida Biosciences, a 16-month-old startup whose lead autoimmune drug is still in Phase 1.
Revolution Medicines' RASONQUE is the first broad RAS-targeted pill for metastatic pancreatic cancer, nearly doubling median survival to 13.2 months. The catch: $39,800 a month.
The FDA cleared Revolution Medicines' daraxonrasib, the first broad RAS-targeted pill for metastatic pancreatic cancer, doubling median survival to 13.2 months at a $477,000-a-year list price.
